World Library  
Flag as Inappropriate
Email this Article

Frovatriptan

Article Id: WHEBN0000692988
Reproduction Date:

Title: Frovatriptan  
Author: World Heritage Encyclopedia
Language: English
Subject: 5-HT1D receptor agonist, Methysergide, Dihydroergotamine, 5-HT receptor, Ergotamine
Collection: Amides, Amines, Carbazoles, Triptans
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Frovatriptan

Frovatriptan
Systematic (IUPAC) name
(+)-(R)-3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
Clinical data
Trade names Frova
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Legal status
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 20–30%
Metabolism Hepatic
Biological half-life 26 hours
Excretion Renal
Identifiers
CAS Registry Number  N
ATC code N02
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  N
ChEMBL  Y
Synonyms 6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
(6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
Chemical data
Formula C14H17N3O
Molecular mass 243.304 g/mol
 N   

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches and for short term prevention of menstrual migraine. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1]

Contents

  • Pharmacology 1
  • Mechanism of action 2
  • Adverse effects 3
  • Contraindications 4
  • US licensing 5
  • References 6
  • External links 7

Pharmacology

Frovatriptan inhibits excessive dilation of arteries that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

Mechanism of action

Frovatriptan is a 5HT receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.

Adverse effects

Serious but rare cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Contraindications

Frovatriptan should not be given to patients with:

  • Ischemic heart disease
  • Cerebrovascular syndrome
  • Peripheral vascular disease
  • Uncontrolled hypertension
  • Hemiplegic or basilar migraine

US licensing

Frovatriptan is available only by prescription in the United States, and Canada where a secondary New Drug Approval (sNDA) was filed in July 2006,[2] and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).

References

  1. ^ "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28. 
  2. ^ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28. 

External links

  • Frova (manufacturer's website)
  • Frovatriptan Succinate (patient information)
  • FDA labeling
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.